Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(146 produtos)
- Bcr-Abl(102 produtos)
- EGFR(572 produtos)
- FAK(72 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(245 produtos)
- PDGFR(126 produtos)
- RAAS(87 produtos)
- Src(79 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(268 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1431 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CTA 056
CAS:<p>CTA 056 is an ITK inhibitor that inhibits the growth of MOLT-4 xenograft tumors in mice and can be used to study autoimmune disorders.</p>Fórmula:C35H34N6OPureza:97.22% - 97.76%Cor e Forma:SolidPeso molecular:554.68CHMFL-EGFR-202
CAS:<p>CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).</p>Fórmula:C25H24ClN7O2Pureza:99.66%Cor e Forma:SolidPeso molecular:489.96EGFR-IN-11
CAS:<p>EGFR-IN-11 selectively blocks EGFR-tyrosine kinase and promotes apoptosis; targets EGFRL858R/T790M/C797S, IC50=18 nM; halts cell cycle at G0/G1.</p>Fórmula:C29H35N9O2SPureza:99.93%Cor e Forma:SolidPeso molecular:573.71Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Fórmula:C29H32Cl2N2O5SPureza:99.51% - 99.83%Cor e Forma:SoildPeso molecular:591.55JNJ-49095397
CAS:<p>JNJ-49095397 (RV568) is a p38 MAPK-α and p38 MAPK-γ kinase inhibitor for the study of respiratory syncytial virus infection.</p>Fórmula:C34H36N6O4Pureza:98.33% - 99.04%Cor e Forma:SolidPeso molecular:592.69STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Fórmula:C15H15ClN4O2Pureza:99.01%Cor e Forma:SolidPeso molecular:318.76c-Fms-IN-3
CAS:c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.Fórmula:C23H30N6OPureza:99.87%Cor e Forma:SolidPeso molecular:406.52TP0427736 hydrochloride
CAS:<p>TP0427736 hydrochloride is a novel and selective ALK5 inhibitor, capable of inhibiting Smad2/3 phosphorylation in A549 cells.</p>Fórmula:C14H11ClN4S2Pureza:98.99%Cor e Forma:SolidPeso molecular:334.85H-9 dihydrochloride
CAS:<p>H-9 dihydrochloride: Strong PKA inhibitor, curbs 5-HT response and EGF signaling, affects pharyngeal function.</p>Fórmula:C11H15Cl2N3O2SPureza:97.3%Cor e Forma:SolidPeso molecular:324.23Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Fórmula:C10H6N2O3Pureza:98.76%Cor e Forma:Yellow Green Powder /Off-White SolidPeso molecular:202.17HIF-2α-IN-3
CAS:<p>HIF-2α-IN-3 is an allosteric inhibitor of HIF-2α (IC50: 0.4 μM; KD: 1.1 μM) with anticancer activity.</p>Fórmula:C12H6ClN5O5Pureza:98.11%Cor e Forma:SolidPeso molecular:335.66JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Fórmula:C33H38F2N6O8Cor e Forma:SolidPeso molecular:684.69JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Fórmula:C18H21N4Na2O6PPureza:98%Cor e Forma:SolidPeso molecular:466.341ALK/ROS1-IN-1
CAS:<p>ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).</p>Fórmula:C30H35F3N6O3Pureza:98%Cor e Forma:SolidPeso molecular:584.63EGFR kinase inhibitor 1
CAS:<p>Potent EGFR blocker; acts on WT, L858R/T790M (IC50: 1.7 nM), less on T790M/C797S; stalls cell cycle, induces apoptosis, deters metastasis.</p>Fórmula:C30H31N7O2Cor e Forma:SolidPeso molecular:521.61Brolucizumab
CAS:<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Pureza:95%Cor e Forma:LiquidBTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Fórmula:C37H42N8O4Cor e Forma:SolidPeso molecular:662.78FGFR-IN-2
CAS:<p>FGFR-IN-2 (compound 1) is a potent inhibitor of FGFR, acting on FGFR1 (IC50: 7.3 nM), FGFR2 (IC50: 4.3 nM), FGFR3 (IC50: 7.6 nM) and FGFR4 (IC50: 11 nM).</p>Fórmula:C25H30N6O2Cor e Forma:SolidPeso molecular:446.54T338C Src-IN-1
CAS:<p>T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).</p>Fórmula:C17H20N6O2SPureza:98%Cor e Forma:SolidPeso molecular:372.44UNC5293
CAS:<p>UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.</p>Fórmula:C30H42N6O2Cor e Forma:SolidPeso molecular:518.69Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Fórmula:C22H20N6O3Cor e Forma:SolidPeso molecular:416.43ALK-IN-6
CAS:<p>ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).</p>Fórmula:C26H29ClD3N5O3SPureza:98%Cor e Forma:SolidPeso molecular:533.1DW10075
CAS:<p>DW10075, a novel potent and highly selective inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.</p>Fórmula:C29H23N5O3Cor e Forma:SolidPeso molecular:489.52Ruxolitinib sulfate
CAS:<p>Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.</p>Fórmula:C17H20N6O4SCor e Forma:SolidPeso molecular:404.45TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Fórmula:C26H27Cl2N5O2Pureza:98%Cor e Forma:SolidPeso molecular:512.43JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Fórmula:C20H24N6O2Pureza:98%Cor e Forma:SolidPeso molecular:380.44Risvodetinib
CAS:<p>Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.</p>Fórmula:C33H34N8O2Cor e Forma:SolidPeso molecular:574.68TIE-2/VEGFR-2 kinase-IN-3
CAS:<p>TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 values</p>Fórmula:C23H17F4N5O3SCor e Forma:SolidPeso molecular:519.47JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Fórmula:C19H17N5O4Pureza:98%Cor e Forma:SolidPeso molecular:379.37EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Fórmula:C28H33BrN7O2PCor e Forma:SolidPeso molecular:610.49FLT3/ITD-IN-4
CAS:<p>FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).</p>Fórmula:C25H22N4O5Cor e Forma:SolidPeso molecular:458.47JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Fórmula:C20H25N5O2Cor e Forma:SolidPeso molecular:367.44BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Fórmula:C16H12BrN5Cor e Forma:SolidPeso molecular:354.2FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Fórmula:C25H26N6O2Pureza:98%Cor e Forma:SolidPeso molecular:442.523BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Fórmula:C21H22Cl2N6OCor e Forma:SolidPeso molecular:445.35Famitinib malate
CAS:<p>Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.</p>Fórmula:C27H33FN4O7Cor e Forma:SolidPeso molecular:544.57KB SRC 4
CAS:<p>KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4</p>Fórmula:C32H23ClN8Pureza:98.83% - 99.34%Cor e Forma:SolidPeso molecular:555.03Roslin 2 bromide
CAS:<p>Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.</p>Fórmula:C13H19BrN4Pureza:99.34%Cor e Forma:SolidPeso molecular:311.22PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Fórmula:C22H21ClN6O2Cor e Forma:SolidPeso molecular:436.89JNJ-17029259
CAS:<p>JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).</p>Fórmula:C26H30N6OPureza:98%Cor e Forma:SolidPeso molecular:442.56SNIPER(TACC3)-11
CAS:<p>SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.</p>Fórmula:C51H66N10O7S2Cor e Forma:SolidPeso molecular:995.26SD 1008
CAS:<p>SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.</p>Fórmula:C18H19NO5Pureza:98%Cor e Forma:SolidPeso molecular:329.35MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Fórmula:C25H16ClF2N5O2Cor e Forma:SolidPeso molecular:491.88BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Fórmula:C26H22ClN5O3Cor e Forma:SolidPeso molecular:487.94BT424
CAS:BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].Fórmula:C22H15BCl2N2O2Pureza:98%Cor e Forma:SolidPeso molecular:421.08HIF-2α-IN-1
CAS:<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Fórmula:C16H8F5NO4SPureza:97.99%Cor e Forma:SolidPeso molecular:405.3EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Fórmula:C32H28BrF3N6O4SCor e Forma:SolidPeso molecular:729.57Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Fórmula:C26H29ClN8OCor e Forma:SolidPeso molecular:505.01HDAC-IN-50
CAS:<p>HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.</p>Fórmula:C31H41N7O4Cor e Forma:SolidPeso molecular:575.7UNC4203
CAS:<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Fórmula:C30H44N6OCor e Forma:SolidPeso molecular:504.71EVT801
CAS:<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Fórmula:C19H21N5O3Pureza:97.4%Cor e Forma:SolidPeso molecular:367.4Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Fórmula:C21H33F3N6O11Pureza:98%Cor e Forma:SolidPeso molecular:602.521BTK inhibitor 13
CAS:<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Fórmula:C29H26FN5O3Pureza:98%Cor e Forma:SolidPeso molecular:511.55FGFR-IN-4
CAS:<p>FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.</p>Fórmula:C24H21N7O2Cor e Forma:SolidPeso molecular:439.47HPK1-IN-2 dihydrochloride
CAS:<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Fórmula:C19H22Cl2N6OSCor e Forma:SolidPeso molecular:453.39FC 11
CAS:<p>FC 11 is a reversible FAK PROTAC Degrader with DC50 of 40-370 pM and degrades pFAKtyr397 in TM3 cells within 3 hours at 100 nM.</p>Fórmula:C41H42F3N13O9SCor e Forma:SolidPeso molecular:949.91HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Cor e Forma:SolidPeso molecular:503.6Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Fórmula:C26H31ClN6O2Pureza:98%Cor e Forma:SolidPeso molecular:495.02ALK/EGFR-IN-2
CAS:<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Fórmula:C27H34ClN7O3SCor e Forma:SolidPeso molecular:572.12HDAC-IN-63
CAS:<p>HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.</p>Fórmula:C25H26Cl2N6O3Cor e Forma:SolidPeso molecular:529.42(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Fórmula:C22H20F2N6O2Pureza:98%Cor e Forma:SolidPeso molecular:438.43BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Fórmula:C22H25BrN4O2Pureza:99.02%Cor e Forma:SolidPeso molecular:457.36MTP
CAS:<p>MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.</p>Fórmula:C29H23F3N4O2Pureza:98%Cor e Forma:SolidPeso molecular:516.51TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Fórmula:C17H21FN6OPureza:98%Cor e Forma:SolidPeso molecular:344.39EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PCor e Forma:SolidPeso molecular:733.68JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Cor e Forma:SolidPeso molecular:488.35FLT3/ITD-IN-5
CAS:FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.Fórmula:C23H25N7O2Cor e Forma:SolidPeso molecular:431.49BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Fórmula:C20H22Cl2N6OCor e Forma:SolidPeso molecular:433.33Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Fórmula:C18H21N5O3Pureza:99.85%Cor e Forma:SolidPeso molecular:355.39BCR-ABL-IN-4
CAS:<p>BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).</p>Fórmula:C27H24ClF2N5O4Cor e Forma:SolidPeso molecular:555.96DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Fórmula:C28H27F2N7O3Pureza:98%Cor e Forma:SolidPeso molecular:547.56Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Fórmula:C20H17N9Pureza:98%Cor e Forma:SolidPeso molecular:383.41PI3K/VEGFR2-IN-1
CAS:<p>PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.</p>Fórmula:C17H14ClN3OSPureza:98%Cor e Forma:SolidPeso molecular:343.83TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Fórmula:C17H11ClF2N4O2Cor e Forma:SolidPeso molecular:376.74YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Fórmula:C30H30N4O3Pureza:98%Cor e Forma:SolidPeso molecular:494.58Infigratinib-Boc
CAS:<p>Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].</p>Fórmula:C29H35Cl2N7O5Cor e Forma:SolidPeso molecular:632.54ALK/EGFR-IN-1
CAS:<p>ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.</p>Fórmula:C27H34ClN7O3SPureza:98%Cor e Forma:SolidPeso molecular:572.12EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Fórmula:C31H34N6O3Cor e Forma:SolidPeso molecular:538.64Irpagratinib
CAS:<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Fórmula:C28H32F2N6O5Pureza:99.08% - 99.38%Cor e Forma:SolidPeso molecular:570.59HDAC/JAK/BRD4-IN-1
CAS:<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Fórmula:C24H28N6O3Pureza:98%Cor e Forma:SolidPeso molecular:448.52SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Fórmula:C28H35ClFN7O3SCor e Forma:SolidPeso molecular:604.14CP-547632 TFA
CAS:<p>CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.</p>Fórmula:C22H25BrF5N5O5SPureza:98%Cor e Forma:SolidPeso molecular:646.43ALK/EGFR-IN-3
CAS:<p>ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-</p>Fórmula:C27H34ClN7O3SCor e Forma:SolidPeso molecular:572.12AT-9283 L-lactate
CAS:<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Fórmula:C22H29N7O5Pureza:98%Cor e Forma:SolidPeso molecular:471.52BPR1J-340
CAS:<p>BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.</p>Fórmula:C29H34N8O3Cor e Forma:SolidPeso molecular:542.63FLT3-IN-14
CAS:<p>FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.</p>Fórmula:C25H24N6O2SCor e Forma:SolidPeso molecular:472.56BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Fórmula:C27H28ClFN8O3Pureza:99.98%Cor e Forma:SolidPeso molecular:567.01JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Fórmula:C22H24N6O3Pureza:98%Cor e Forma:SolidPeso molecular:420.46Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Fórmula:C30H37N7O2Cor e Forma:SolidPeso molecular:527.66BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Fórmula:C26H23N7O2Cor e Forma:SolidPeso molecular:465.51PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Fórmula:C23H18ClF2N3O2SPureza:98.84%Cor e Forma:SolidPeso molecular:473.92Atiprimod dimaleate
CAS:Atiprimod Dimaleate is a JAK2 inhibitor.Fórmula:C30H52N2O8Cor e Forma:SolidPeso molecular:568.74Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Fórmula:C25H26ClFN4O4Pureza:99.7%Cor e Forma:SolidPeso molecular:500.95TIE-2/VEGFR-2 kinase-IN-4
CAS:<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Fórmula:C26H17F4N5O4Cor e Forma:SolidPeso molecular:539.44Sulfatinib
CAS:<p>Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to</p>Fórmula:C24H28N6O3SPureza:99.21% - >99.99%Cor e Forma:SolidPeso molecular:480.58CCT365623 hydrochloride
CAS:<p>CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.</p>Fórmula:C18H18ClNO4S3Pureza:98%Cor e Forma:SolidPeso molecular:443.99EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Fórmula:C26H25ClN6O2Cor e Forma:SolidPeso molecular:488.97CT-721
CAS:<p>CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.</p>Fórmula:C30H29ClN6OPureza:98%Cor e Forma:SolidPeso molecular:525.04Pivanex
CAS:<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Fórmula:C10H18O4Pureza:≥98%Cor e Forma:SolidPeso molecular:202.25(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Fórmula:C16H14N2O2Cor e Forma:SolidPeso molecular:266.29
